- Conditions
- Graft-versus-host Disease (GVHD)
- Interventions
- Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 38
- States / cities
- Tucson, Arizona • Duarte, California • La Jolla, California + 28 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 28
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Stem Cell Leukemia of Unclear Lineage, Graft Versus Host Disease
- Interventions
- extracorporeal photopheresis
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- Itacitinib, Extracorporeal Photopheresis (ECP)
- Drug · Device
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- INCA034176, Best available Treatment (BAT)
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 11
- States / cities
- Duarte, California • Los Angeles, California • Palo Alto, California + 8 more
- Conditions
- Cutaneous T Cell Lymphoma, Mycosis Fungoides
- Interventions
- Methoxsalen+ECP
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
- Conditions
- Cutaneous T Cell Lymphoma, Graft Versus Host Disease
- Interventions
- Not listed
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- Aldesleukin, Extracorporeal Photopheresis, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Biological · Procedure · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Graft Versus Host Disease
- Interventions
- stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis), etanercept, methoxsalen
- Procedure · Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Steroid Refractory Acute Graft Versus Host Disease
- Interventions
- Methoxsalen, Extracorporeal Photopheresis (ECP)
- Drug · Procedure
- Lead sponsor
- Therakos, Inc., a Mallinckrodt Company
- Industry
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 13 more
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- SoluMedrol, Extracorporeal Photopheresis
- Drug · Device
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- Extracorporeal Photopheresis (ECP), Interleukin-2
- Procedure · Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Sezary Syndrome
- Interventions
- Extracorporeal photopheresis (ECP), Methoxsalen Injection
- Device · Drug
- Lead sponsor
- Oleg E. Akilov, MD, PhD
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Pittsburgh, Pennsylvania
- Conditions
- Graft Versus Host Disease
- Interventions
- Allogeneic mesenchymal stromal cells (MSCs), Extracorporeal photopheresis (ECP)
- Biological
- Lead sponsor
- Molly Gallogly
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Crohn's Disease
- Interventions
- Methoxsalen +ECP, Extracorporeal Photopheresis
- Drug · Procedure
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 4
- States / cities
- Bethesda, Maryland • Chevy Chase, Maryland • Morristown, New Jersey + 1 more
- Conditions
- Leukemia, Cancer
- Interventions
- Extracorporeal Photopheresis
- Procedure
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- Not listed
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome
- Interventions
- Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment
- Procedure · Biological · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Graft Versus Host Disease, Cancer, Stem Cell Transplantation
- Interventions
- Extracorporeal Photopheresis
- Procedure
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- GVHD
- Interventions
- blood samples
- Other
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Graft Versus Host Disease (GVHD)
- Interventions
- extracorporeal photopheresis, laboratory biomarker analysis
- Procedure · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Nashville, Tennessee + 1 more
- Conditions
- Bronchiolitis Obliterans Syndrome (BOS)
- Interventions
- Extracorporeal Photopheresis (ECP), No intervention in the SOC / Retrospective Chart review.
- Combination Product · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
- Conditions
- Chronic Graft Versus Host Disease, cGVHD
- Interventions
- Axatilimab, Extracorporeal Photopheresis
- Biological · Procedure
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 3
- States / cities
- San Francisco, California • Miami, Florida • Chicago, Illinois
- Conditions
- Cutaneous T Cell Lymphoma, Mycosis Fungoides
- Interventions
- UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis, THERAKOS® CELLEX photopheresis system
- Drug · Device
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Folliculotropic Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Transformed Mycosis Fungoides
- Interventions
- Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Biological · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Duarte, California • Atlanta, Georgia
- Conditions
- Hematologic Malignancies
- Interventions
- extracorporeal photopheresis, Pentostatin, Total Body Irradiation
- Procedure · Drug · Radiation
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Boston, Massachusetts • San Antonio, Texas